ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.344,88
0,30%
S&P 500
5.667,56
0,08%
US Dollar vs BRL
5,7346
-0,01%
Bitcoin
84.171,85
0,15%
Brent Oil
71,775
0,00%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Recursion Pharmaceuticals Inc (RXRX)

  7. Recursion Pharmaceuticals Inc (RXRX) Notícias

RXRX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RXRX
DataHoraFonteTítuloCódigoCompanhia
19/03/202517:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
19/03/202517:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
18/03/202509:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
18/03/202509:00GlobeNewswire Inc.Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine SunNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/03/202513:55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
28/02/202509:26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
28/02/202508:33Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RXRXRecursion Pharmaceuticals Inc
28/02/202508:30GlobeNewswire Inc.Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
24/02/202510:00GlobeNewswire Inc.Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28thNASDAQ:RXRXRecursion Pharmaceuticals Inc
19/02/202511:00GlobeNewswire Inc.Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake CityNASDAQ:RXRXRecursion Pharmaceuticals Inc
18/02/202513:00GlobeNewswire Inc.Altitude Lab Startups Raise $154M in CapitalNASDAQ:RXRXRecursion Pharmaceuticals Inc
14/02/202513:23Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
12/02/202519:07Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RXRXRecursion Pharmaceuticals Inc
05/02/202519:24GlobeNewswire Inc.Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
17/01/202519:58PR Newswire (US)Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028NASDAQ:RXRXRecursion Pharmaceuticals Inc
07/01/202511:15GlobeNewswire Inc.Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & MoreNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/01/202510:30GlobeNewswire Inc.Recursion to Present at 43rd Annual JP Morgan Healthcare ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/12/202418:05GlobeNewswire Inc.Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesNASDAQ:RXRXRecursion Pharmaceuticals Inc
17/12/202419:05Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
09/12/202420:00GlobeNewswire Inc.Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable TolerabilityNASDAQ:RXRXRecursion Pharmaceuticals Inc
03/12/202410:30GlobeNewswire Inc.Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and LymphomaNASDAQ:RXRXRecursion Pharmaceuticals Inc
27/11/202418:09Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
20/11/202409:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/11/202409:00GlobeNewswire Inc.Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discoveryNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/11/202411:08GlobeNewswire Inc.Recursion and Exscientia Shareholders Approve the Proposed CombinationNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/11/202418:54GlobeNewswire Inc.Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model GardenNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/11/202416:17Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
06/11/202418:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
06/11/202418:15GlobeNewswire Inc.Recursion Provides Business Updates and Reports Third Quarter 2024 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/11/202408:12Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RXRXRecursion Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RXRX

Seu Histórico Recente

EU
CEAAG
Bas Rhin department 0.04...
EU
ALESE
Entech
COIN
PRICEUSD
PriceCoin
LSE
32XA
Westpac 36
EU
VDMOC
Voyageurs du Monde Domes...
EU
CCFAC
HSBC France Domestic bon...
LSE
0OPN
Financiere De L'odet
EU
HSBCB
Hsbc France 2.136% may2038
TG
OXQ1
Arq
TSX
CURA
Curaleaf
LSE
RSI
LSE
REE
Altona Rare Earths
Delayed Upgrade Clock
ADVFN Logo
Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios